All News

pregnancy,birth,preterm,baby

Increased Preterm Birth Risk in Psoriatic Arthritis Pregnancies

d Jack Cush, MD

Pregnancy outcomes may be affected by psoriatic arthritis or antirheumatic treatment; registry cohort study shows that preterm birth and cesarean delivery were mostly increased by antirheumatic treatment, especially biologics.

Read Article
RheumNow Podcast square

RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)

d Jack Cush, MD

Today I have a few questions: Is tramadol really a weak narcotic? Should we really still be doing placebo-controlled trials? What are we going to do about our patients who are smokers? This and more, in this week's review of the news and journal articles.

Read Article
smoking.jpg

Smoking Impairs Methotrexate Efficacy

d Jack Cush, MD

The Journal of Rheumatology reports that current smoking significantly reduces the clinical efficacy of methotrexate (MTX)-based therapy, as studied in an early rheumatoid arthritis (RA) cohort.

Read Article
Among 825,556 sepsis pts in Taiwan (2003–2017), having SLE increased mortality risk 3 fold (HR 2.8;2.5–3.2), w/ adjustments (HR 1.47). Other risk factors: age (1.02), prednisolone > 5mg/d (1.55), MTX (2.19) & immunosuppressives (1.45) https://t.co/d1OPrjgshz

Links:

Dr. John Cush RheumNow ( View Tweet)

Israeli study of 1497 fully vaccinated health care workers finds 39 (2.4% Breakthrough COVID infections (Jan-May 2021), most cases were mild or asymptomatic, 19% w/ persistent Sxs (>6 ws); infected had lower neutralizing Abs. https://t.co/deYTVLRQCU

Links:

Dr. John Cush RheumNow ( View Tweet)

ATOM study - Phase 3 RCT testing abaloparatide (Tymlos) in 228 men with osteoporosis. At 12 mos Tymlos shows signif increase in lumbar BMD of 1.2%. Also increased were hip and femoral neck BMD at 12 months. https://t.co/WC3ygkyMZH

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester(OR 4.55),BMI >30 (6.14),antiphospholipid synd (8.02),hx preeclampsia (9.8)https://t.co/giBamMAPRM https://t.co/NHKxlmEHQj

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Smoke-Enders available for download wherever you get your podcasts. https://t.co/o35tuNgk8R https://t.co/pksojrC5Wb

Links:

Dr. John Cush RheumNow ( View Tweet)
"Progress is a nice word. But change is its motivator and change has its enemies." - Robert F. Kennedy https://t.co/sIVym3e80c
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao https://t.co/0p8RGnnE9B

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://t.co/nBUe5VV1D3 https://t.co/C3r0Fur4xJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI:Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d.(Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies. https://t.co/pMXWmuJw5Y https://t.co/RhWdVir6yB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU https://t.co/8y5asZ7NWq

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast up! Rheumatologist Smoke-Enders https://t.co/o35tuNgk8R https://t.co/iEqVoggl32

Links:

Dr. John Cush RheumNow ( View Tweet)
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights Read the full article on #RheumNow https://t.co/294Au0Q1c3 https://t.co/c1X2T5G4jW

Links:

Dr. John Cush RheumNow ( View Tweet)
RECOVERY study of hospitalized COVID-19 pts compared colchicine to PBO (+usual care). Colchicine had no effect on 28d mortality (21% vs 21%), time to D/C(10 d vs 10d), LIve D/C (70 vs 70%), mechanical vent or death (25 vs 25%) https://t.co/dYZglKzwxC

Links:

Dr. John Cush RheumNow ( View Tweet)

Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao

Links:

Dr. John Cush RheumNow ( View Tweet)

Propensity matched comparison of Tramadol vs Codeine use. Tramadol had a signif. higher risk of all-cause mortality (HR, 2.31), CV events (HR 1.15) & fractures (HR 1.50), but no diff in falls, delirium, constipation, opioid abuse, sleep disorders. https://t.co/nBUe5VV1D3 https://t.co/DHzrXQ2nr1

Links:

Dr. John Cush RheumNow ( View Tweet)
×